4.5 Article

Impact of Physical and Sexual Abuse on Treatment Response in the Treatment of Resistant Depression in Adolescent Study (TORDIA)

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jaac.2010.11.019

Keywords

depression; cognitive behavioral therapy; abuse; selective serotonin reuptake inhibitor

Funding

  1. National Institute of Mental Health (NIMH) [MH61835, MH61856, MH61864, MH61869, MH61958, MH62014, MH66371]
  2. Philip Morris
  3. Bristol-Myers Squibb
  4. National Institute of Mental Health
  5. Dey Pharma, L.P.
  6. Pfizer
  7. Seaside Pharmaceuticals
  8. Aspect
  9. Biobehaviorol Diagnostics
  10. Eli Lilly and Co., Forest
  11. GlaxoSmithKline
  12. GlaxoSmithKline, and Somerset

Ask authors/readers for more resources

Objective: We previously reported that a history of abuse was associated with a poorer response to combination treatment in the Treatment of Resistant Depression in Adolescents study (TORDIA). We now report on the nature and correlates of abuse that might explain these findings. Method: Youth who did not benefit from an adequate selective serotonin re-uptake inhibitor (SSRI) trial (N = 334) were randomized to one of the following: an alternative SSRI; an alternative SSRI plus cognitive behavior therapy (CBT); venlafaxine; or venlafaxine plus CBT. Analyses examined the effect of history of abuse on response to the pharmacotherapy and combination therapy. Results: Those without a history of physical abuse (PA) or sexual abuse (SA) had a higher 12-week response rate to combination therapy compared with medication mono-therapy (62.8% versus 37.6%; odds ratio [OR] = 2.8, 95% confidence interval [CI] = 1.6-4.7, p < .001). Those with a history of SA had similar response rates to combination versus medication monotherapy (48.3% versus 42.3%; OR = 1.3, 95% CI = 0.4-3.7; p = .66), whereas those with history of PA had a much lower rate of response to combination therapy (18.4% versus 52.4%, OR = 0.1; 95% CI = 0.02-0.43). Even after adjusting for other clinical predictors, a history of PA moderated treatment outcome. Conclusion: These results should be considered within the limitations of a post hoc analysis, lack of detailed assessment of abuse and other forms of trauma, and neuropsychological status. Depressed patients with history of abuse, especially PA may require specialized clinical approaches. Further work is needed to understand by what mechanisms a history of abuse affects treatment response. J. Am. Acad. Child Adolesc. Psychiatry, 2011;50(3):293-301. Clinical Trial Registry Information: Treatment of SSIZI-Resistant Depression in Adolescents (TORDIA); NCT00018902; http://www.clinicaltrials.gov.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available